Compounded Tirzepatide Therapy for Weight Loss: A Health Economics & Outcomes Research (HEOR) Analysis.
Feb 8, 2025International journal of pharmaceutical compounding
Cost and results of combined tirzepatide treatment for weight loss
AI simplified
Abstract
A 5% reduction in body weight was achieved after four weeks of compounded tirzepatide therapy.
- The investigator's body mass index (BMI) decreased to 25.8 but did not meet the target of 25.
- Weight was regained within two weeks after stopping the therapy, reflecting a potential relapse similar to real-world outcomes.
- Side effects included bloating, increased thirst, and rapid intestinal emptying, which could be intolerable in a work setting.
- Weight-lifting strength was maintained, lap swimming speed remained stable, and endurance improved during the treatment period.
- Behavioral changes related to food cravings and exercise performance were observed but may be influenced by performance bias.
AI simplified
OBJECTIVE: A male health outcomes investigator, in age bracket 55 - 65, with BMI = 27 kg/m2, but without type 2 diabetes, took compounded tirzepatide 7.5 mg/week therapy as an experiment to see if he could achieve a 10% reduction in body weight over approximately four weeks and restore BMI = 25 kg/m2. Secondary endpoints included maintenance of weight-lifting strength, maintenance of speed and endurance in lap swimming, and maintenance of a nutrient-dense vegan diet. This study was undertaken to address some of the claims currently circulating in popular media about tirzepatide and the glucagon-like peptide 1 receptor agonist (GLP-1 RA) class of injectable drugs. All previous medical journal articles that mention the active pharmaceutical ingredient (API) tirzepatide have referred to the branded drug, while this article is the first one focused on compounded tirzepatide.
METHODS: The investigator received weekly subcutaneous injections of 7.5 mg compounded tirzepatide over four weeks at a cost of $400 for four prefilled syringes. In the first, third, and fourth weeks, the investigator received 7.5 mg of compounded tirzepatide as a bolus injection. In week 2, the 7.5 mg dose was distributed over two injections of approximately 3.75 mg each given two days apart. The investigator recorded any lifestyle changes or changes in eating habits that resulted from this short duration study on the effects of tirzepatide for weight loss.
RESULTS: With four weeks of compounded tirzepatide therapy, the investigator achieved a 5% reduction in body weight and a BMI of 25.8. Despite continuing to participate in daily exercise, having a healthy vegan diet, and supplementing with many vitamins, minerals, electrolytes, and nutrient-dense foods, the investigator regained 5% body weight within two weeks after the conclusion of the study. The investigator experienced side effects similar to those reported for GLP-1 RA class of injectable drugs, including tirzepatide. However, the treatment revealed an undulating pattern in which the compounded tirzepatide injection produced the desired effects, but intermittently the patient experienced neither a sense of satiety nor a sense of delayed digestion post injections, therefore, ate a normal meal and/or snacks. Adverse events included generalized bloating and flatulence, carbohydrate-specific temporary weight gain and bloating, intestinal rapid emptying comparable to excessive laxative use, and profound thirst with water consumption approximately double his normal level. Weight-lifting strength was maintained across a wide variety of equipment stations; lap swimming speed was maintained, and endurance was increased on compounded tirzepatide therapy. Apparent negative and positive neuroplasticity in the study period enabled the investigator to overcome a craving for one high caloric sugary snack, and to overcome an endurance barrier in the laps swam per set and per workout. These two results might be explained by performance bias, which arises from behavioral changes by participants or researchers due to awareness of the assigned interventions.
CONCLUSIONS: The compounded tirzepatide tested in this 4-week study produced less weight loss than was intended and side effects that would be intolerable in a work environment with nearby colleagues. Compounded tirzepatide was a useful tool to enable this study of the dual glucose-dependent insulinotropic polypeptide (GIP), also known as gastric inhibitory polypeptide, and GLP-1 RA class of drugs in chronic weight management. However, a 7.5 mg weekly dose of compounded API tirzepatide over four weeks is unlikely to produce a lasting 10% reduction in body weight even for those patients practicing intermittent fasting, choosing a vegan diet, and performing weight-bearing exercise and cardiovascular exercise daily. After cessation of therapy, the investigator's lost weight was regained, representing the weight gain relapse observed in some real-world settings associated with injectable weight loss drugs. Arguably, the dual GIP RA and GLP-1 RA drugs take patients on a proverbial roller coaster ride of weight loss and regain and intense yo-yo dieting. Patients on tirzepatide or semaglutide might benefit most not from realizing some short-term weight loss goal, but from lasting neuroplasticity-like changes in memory, rewards, and elimination of one or more particular food cravings based on the brain's ability to create, organize, and reorganize connections between neurons.
Related papers
Dec '23
Ongoing Tirzepatide Treatment May Help Adults With Obesity Keep Weight Off
top 1% journal
cited by 575 papers
randomized controlled trial
Sep '22
Tirzepatide, a medicine targeting two hormone receptors, may better control blood sugar and reduce weight in type 2 diabetes
top 2% journal
cited by 290 papers
research support, non-u.s. gov't
Feb '24
Simulated blood sugar and weight loss changes when switching weekly diabetes medication from semaglutide or dulaglutide to tirzepatide
top 30% journal
cited by 6 papers
journal article
Apr '25
Real-world use, benefits, and side effects of new weight-loss treatments based on GLP-1 receptor activators
top 5% journal
cited by 81 papers
journal article
May '22
Managing type 2 diabetes with tirzepatide, a drug targeting two blood sugar hormones: a review and combined analysis
top 2% journal
cited by 217 papers
systematic review
Nov '24
Why combining GLP-1 with GIP and/or GCG agonists causes more weight loss than GLP-1 alone in obese adults without diabetes
top 5% journal
cited by 13 papers
journal article
Jun '20
Tirzepatide briefly slows stomach emptying like long-acting GLP-1 receptor drugs
top 5% journal
cited by 111 papers
research support, non-u.s. gov't
Apr '22
Tirzepatide compared to placebo or semaglutide on insulin production and sensitivity in adults with type 2 diabetes
top 1% journal
cited by 212 papers
randomized controlled trial